NLS Pharmaceutics (NLSP) Competitors $1.91 -0.13 (-6.37%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NLSP vs. AKTX, CGTX, LSTA, INKT, KALA, CVM, MRNS, DARE, UBX, and VRCAShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Akari Therapeutics (AKTX), Cognition Therapeutics (CGTX), Lisata Therapeutics (LSTA), MiNK Therapeutics (INKT), KALA BIO (KALA), CEL-SCI (CVM), Marinus Pharmaceuticals (MRNS), Daré Bioscience (DARE), Unity Biotechnology (UBX), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Akari Therapeutics Cognition Therapeutics Lisata Therapeutics MiNK Therapeutics KALA BIO CEL-SCI Marinus Pharmaceuticals Daré Bioscience Unity Biotechnology Verrica Pharmaceuticals Akari Therapeutics (NASDAQ:AKTX) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability. Does the MarketBeat Community believe in AKTX or NLSP? Akari Therapeutics received 254 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. However, 57.14% of users gave NLS Pharmaceutics an outperform vote while only 51.07% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26251.07% Underperform Votes25148.93% NLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Do institutionals & insiders have more ownership in AKTX or NLSP? 5.1% of Akari Therapeutics shares are held by institutional investors. 38.9% of Akari Therapeutics shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, AKTX or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/ANLS PharmaceuticsN/AN/A-$12.17MN/AN/A Is AKTX or NLSP more profitable? Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A NLS Pharmaceutics N/A N/A N/A Does the media refer more to AKTX or NLSP? In the previous week, NLS Pharmaceutics had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 0 mentions for Akari Therapeutics. NLS Pharmaceutics' average media sentiment score of -0.07 beat Akari Therapeutics' score of -0.50 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Overall Sentiment Akari Therapeutics Negative NLS Pharmaceutics Neutral Which has more risk & volatility, AKTX or NLSP? Akari Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. SummaryAkari Therapeutics beats NLS Pharmaceutics on 5 of the 8 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.29M$6.50B$5.34B$9.12BDividend YieldN/A2.95%5.37%4.01%P/E RatioN/A4.3657.4613.13Price / SalesN/A310.771,272.2275.82Price / CashN/A22.8736.6632.72Price / BookN/A4.964.884.58Net Income-$12.17M$154.90M$118.05M$224.83M7 Day Performance-5.91%1.35%1.45%2.37%1 Month Performance-2.05%0.41%2.50%4.40%1 Year Performance297.92%3.08%25.79%20.10% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.91-6.4%N/A+297.9%$7.29MN/A0.006Gap DownAKTXAkari TherapeuticsN/A$1.19-2.1%N/A-53.7%$31.50MN/A0.009Analyst ForecastCGTXCognition Therapeutics2.5288 of 5 stars$0.74-2.7%$8.30+1,020.6%-70.4%$30.78MN/A-0.7620Gap DownLSTALisata Therapeutics3.0146 of 5 stars$3.66-1.9%$15.00+309.8%+25.8%$30.73MN/A-1.4630Positive NewsINKTMiNK Therapeutics2.4589 of 5 stars$0.77+5.4%$6.50+743.4%+0.0%$30.54MN/A-1.9830Gap UpKALAKALA BIO4.1002 of 5 stars$6.60-3.1%$15.00+127.3%-2.3%$30.43M$3.89M-0.5330Negative NewsCVMCEL-SCIN/A$0.41-4.5%N/A-83.4%$30.05MN/A-0.7043Gap UpMRNSMarinus Pharmaceuticals4.606 of 5 stars$0.54+0.7%$4.79+784.6%-94.4%$29.87M$31.47M-0.22110Analyst ForecastDAREDaré Bioscience1.2681 of 5 stars$3.37+8.0%$24.00+612.2%-10.2%$29.32M$1.88M-5.7130News CoveragePositive NewsUBXUnity Biotechnology4.4282 of 5 stars$1.72-3.9%$7.33+326.4%+3.6%$28.98M$240,000.00-1.3160VRCAVerrica Pharmaceuticals4.0806 of 5 stars$0.64-3.8%$9.50+1,395.4%-88.5%$28.97M$9.21M-0.3540 Related Companies and Tools Related Companies Akari Therapeutics Alternatives Cognition Therapeutics Alternatives Lisata Therapeutics Alternatives MiNK Therapeutics Alternatives KALA BIO Alternatives CEL-SCI Alternatives Marinus Pharmaceuticals Alternatives Daré Bioscience Alternatives Unity Biotechnology Alternatives Verrica Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLSP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
